Previous research has demonstrated that patients with type 2 diabetes (T2DM) are at an increased risk for cardiovascular events, including heart failure (HF). Moreover, there is a higher risk of mortality in individuals who have both T2DM and HF with preserved ejection fraction (HFpEF). Although there are antidiabetic agents that have shown both cardiovascular safety and improved cardiovascular outcomes, only certain agents have been associated with HF benefits, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors. This study aims to review the pathophysiology of HFpEF in the setting of T2DM and, more specifically, the role of SGLT2 inhibitors in HFpEF outcomes.

先前的研究表明，2 型糖尿病 (T2DM) 患者发生心血管事件的风险增加，包括心力衰竭 (HF)。此外，同时患有 T2DM 和 HF 且射血分数保留 (HFpEF) 的个体的死亡风险更高。尽管有一些抗糖尿病药物既显示了心血管安全性又改善了心血管结果，但只有某些药物与 HF 益处相关，例如钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂。本研究旨在回顾 HFpEF 在 T2DM 中的病理生理学，更具体地说，是回顾 SGLT2 抑制剂在 HFpEF 结局中的作用。